October - December 2010
November 11, 2010
Takeda Pharmaceutical Company Limited
Osaka, Japan – November 11th, 2010 and Seattle, WA –November 10th, 2010 – Takeda Pharmaceutical Company Limited (TSE: 4502), a global pharmaceutical company, and Sage Bionetworks, a new strategic nonprofit biomedical research organization, today announced that they have formed a four-year research alliance that will focus on discovering effective therapeutic targets for Central Nervous System (CNS) disease.
The Sage Bionetworks team of network biologists*1, systems biologists*2, statistical geneticists*3 and computational biologists*4 use coherent datasets containing clinical, genetic and molecular layers of information to virtually build advanced predictive models of disease*5.
Using its integrated genomics methods, Sage’s scientists will build a predictive model and identify key regulatory genes and predictive biomarkers in patients with CNS disease. Scientists at the two companies will then work together to discover and prioritize the targets that hold the greatest potential for molecular intervention. Under the terms of the agreement, Takeda will provide more than $3.6 million over four years in research funding and fees.
“We excited about the great synergy between Sage’s network biology technology and Takeda’s proven expertise in pharmaceutical research and development,” said Dr. Stephen Friend, President of Sage Bionetworks. “We believe this project, which is the first in Central Nervous System area, creates an opportunity for new therapeutic insights.”
“Sage Bionetworks’ leading-edge technology and world-wide reach offer the potential for Takeda to understand currently unknown disease mechanism. This represents a key strategy for meeting Takeda’s challenge for innovation,” said Dr. Paul Chapman, General Manager, Head of Pharmaceutical Research Division of Takeda Pharmaceutical Company Limited. “We view this collaboration as an opportunity to further Takeda’s goal of identifying targets for new therapeutics to treat the serious effects of CNS diseases where there is a high unmet need for patients all over the world.
*1 Network biology studies networks of biological objects such as DNA, proteins, RNA.
*2 System biology is an inter-disciplinary study field that focuses on complex interactions in biological systems.
*3 Statistical genetics is a study analyzing genetics information by statistical method.
*4 Computational biology is an inter-disciplinary study field that applies the techniques of computer science, applied mathematics and statistics.
*5 Predictive model of disease is an integrated approach to explore the molecular mechanisms that drive disease. Key to this approach is to map correlation of each gene and develop network modeling. Using this approach, one can identify key group of genes and networks that lead to diseases, and that therefore define at the molecular level disease states.
Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.
Sage Bionetworks is a nonprofit medical research organization established in 2009 to develop a new paradigm for addressing the complexity of human biological information and the treatment of disease. Sage and its academic and commercial partners employ multiple comprehensive molecular and clinical datasets to create validated disease models that improve the speed and efficiency of therapeutic drug development. Sage’s vision is to create an open access, integrative bionetwork evolved by contributor scientists working to eliminate human disease: www.sagebase.org.
Takeda Pharmaceutical Company Limited
Director of Communications